Masaki Kato

4.0k total citations
123 papers, 2.5k citations indexed

About

Masaki Kato is a scholar working on Psychiatry and Mental health, Pharmacology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Masaki Kato has authored 123 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Psychiatry and Mental health, 49 papers in Pharmacology and 24 papers in Cellular and Molecular Neuroscience. Recurrent topics in Masaki Kato's work include Treatment of Major Depression (49 papers), Bipolar Disorder and Treatment (39 papers) and Schizophrenia research and treatment (29 papers). Masaki Kato is often cited by papers focused on Treatment of Major Depression (49 papers), Bipolar Disorder and Treatment (39 papers) and Schizophrenia research and treatment (29 papers). Masaki Kato collaborates with scholars based in Japan, Italy and United States. Masaki Kato's co-authors include Alessandro Serretti, Toshihiko Kinoshita, Diana De Ronchi, Yoshiteru Takekita, Masataka Wakeno, Gaku Okugawa, Junichi Azuma, Tsuyoshi Fukuda, Yuka Ikenaga and James L. Kennedy and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Scientific Reports.

In The Last Decade

Masaki Kato

109 papers receiving 2.4k citations

Peers

Countries citing papers authored by Masaki Kato

Since Specialization

Citations

This map shows the geographic impact of Masaki Kato's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Masaki Kato with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Masaki Kato more than expected).

Fields of papers citing papers by Masaki Kato

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Masaki Kato. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Masaki Kato. The network helps show where Masaki Kato may publish in the future.

Co-authorship network of co-authors of Masaki Kato

This figure shows the co-authorship network connecting the top 25 collaborators of Masaki Kato. A scholar is included among the top collaborators of Masaki Kato based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Masaki Kato. Masaki Kato is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy of Pharmacological Interventions in Milder Depression: A Systematic Review and Meta‐Analysis 2025 ·Neuropsychopharmacology Reports ·(unknown), Hitoshi Sakurai, Fumihiko Ueno, (unknown), (unknown), (unknown), Yasuyuki Matsumoto, (unknown), Masayuki Tomita, Hajime Baba, Masaki Kato, Takashi Tsuboi, (unknown)	0
2	Goal Attainment Scaling for Depression: Validation of the Japanese GAS-D Tool in Patients with Major Depressive Disorder 2024 ·Neuropsychiatric Disease and Treatment ·Masaki Kato, Toshiaki Kikuchi, Koichiro Watanabe, Tomiki Sumiyoshi, Yoshiya Moriguchi, Daniel Oudin Åström, Michael Cronquist Christensen	2
3	Antidepressants available in Japan for older people with major depressive disorder: A systematic review and meta‐analysis 2024 ·Neuropsychopharmacology Reports ·Taro Kishi, Kenji Sakuma, Masakazu Hatano, Takenori Okumura, Masaki Kato, Hajime Baba, Nakao Iwata	1
4	A Multicenter, Open-Label Study to Evaluate the Long-term Safety and Efficacy of Adjunctive Brexpiprazole 2 mg Daily in Japanese Patients with Major Depressive Disorder 2024 ·CNS Drugs ·Masaki Kato, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Kazuo Aoki, Yuki Shiomi, Teruhiko Higuchi	0
5	The Burden of Attention-Deficit/Hyperactivity Disorder Traits in Adult Patients with Major Depressive Disorder in Japan 2023 ·Neuropsychiatric Disease and Treatment ·Masaki Kato, (unknown), Yirong Chen, Toshinaga Tsuji, Nobuhiro Nishigaki	3
6	Assessing Reliability and Validity of the Oxford Depression Questionnaire (ODQ) in a Japanese Clinical Population 2023 ·Neuropsychiatric Disease and Treatment ·Masaki Kato, Toshiaki Kikuchi, Koichiro Watanabe, Tomiki Sumiyoshi, Yoshiya Moriguchi, Daniel Oudin Åström, Michael Cronquist Christensen	0
7	Efficacy and safety of zuranolone in Japanese adults with major depressive disorder: A double‐blind, randomized, placebo‐controlled, phase 2 clinical trial 2023 ·Psychiatry and Clinical Neurosciences ·Masaki Kato, Kazuyuki Nakagome, (unknown), Takuhiro Sonoyama, Daiki Okutsu, (unknown), Ryosuke Shimizu, (unknown), Takeshi Inoue	17
8	Safety profile of antidepressant for Japanese adults with major depressive disorder: A systematic review and network meta‐analysis 2023 ·Psychiatry and Clinical Neurosciences ·Taro Kishi, Toshikazu Ikuta, Kenji Sakuma, Masakazu Hatano, Yuki Matsuda, (unknown), Nobumi Miyake, Itaru Miura, Masaki Kato, Nakao Iwata	1
9	Determinants of three-year clinical outcomes in real-world outpatients with bipolar disorder: The multicenter treatment survey for bipolar disorder in psychiatric outpatient clinics (MUSUBI) 2022 ·Journal of Psychiatric Research ·Norio Sugawara, Naoto Adachi, (unknown), Yoichiro Watanabe, (unknown), Takaharu Azekawa, (unknown), Eiichi Katsumoto, Seiji Hongo, (unknown), Hitoshi Ueda, Masaki Kato, Reiji Yoshimura, Atsuo Nakagawa, Toshiaki Kikuchi, Takashi Tsuboi, Koichiro Watanabe, Kazutaka Shimoda, Norio Yasui‐Furukori	3
10	Multiple Pre-Treatment miRNAs Levels in Untreated Major Depressive Disorder Patients Predict Early Response to Antidepressants and Interact with Key Pathways 2022 ·International Journal of Molecular Sciences ·Masaki Kato, Haruhiko Ogata, Hidetoshi Tahara, Akira Shimamoto, Yoshiteru Takekita, Yosuke Koshikawa, Keiichiro Nishida, Shinpei Nonen, Koichiro Higasa, Toshihiko Kinoshita	15
11	Clustering patients by depression symptoms to predict venlafaxine ER antidepressant efficacy: Individual patient data analysis 2020 ·Journal of Psychiatric Research ·Masaki Kato, Yuko Asami, Dalia Wajsbrot, Xuemei Wang, Matthieu Boucher, Rita Prieto, Elizabeth Pappadopulos	6
12	Brain Volume-Related Polymorphisms of the Glycogen Synthase Kinase-3β Gene and Their Effect on Antidepressant Treatment in Major Depressive Disorder 2019 ·Neuropsychobiology ·(unknown), Yoshiteru Takekita, Shinpei Nonen, Masataka Wakeno, Yosuke Koshikawa, Haruhiko Ogata, Toshihiko Kinoshita, Masaki Kato	5
13	[Prediction and Personalized Medicine of Antidepressant Treatment in Japanese MDD Patient]. 2016 ·PubMed ·Masaki Kato	1
14	The Comparative Effects of Risperidone Long-Acting Injection and Paliperidone Palmitate on Social Functioning in Schizophrenia: A 6-Month, Open-Label, Randomized Controlled Pilot Trial 2016 ·Neuropsychobiology ·Yosuke Koshikawa, Yoshiteru Takekita, Masaki Kato, (unknown), (unknown), (unknown), Keiichiro Nishida, Masafumi Yoshimura, Chiara Fabbri, Alessandro Serretti, Toshihiko Kinoshita	23
15	[Possibility of a pharmacogenetic approach for prediction and personalized medication in major depressive disorder treatment]. 2010 ·PubMed ·Masaki Kato	1
16	[5-HT1A gene polymorphisms contributed to antidepressant response in major depression]. 2009 ·PubMed ·Masaki Kato, Takeshi Fukuda, (unknown), Gaku Okugawa, Yoshiteru Takekita, Alessandro Serretti, Junichi Azuma, Toshihiko Kinoshita	3
17	Effect of 5‐HT1A gene polymorphisms on antidepressant response in major depressive disorder 2008 ·American Journal of Medical Genetics Part B Neuropsychiatric Genetics ·Masaki Kato, Tsuyoshi Fukuda, Masataka Wakeno, Gaku Okugawa, Yoshiteru Takekita, (unknown), Megumi Yamashita, (unknown), Junichi Azuma, Toshihiko Kinoshita, Alessandro Serretti	76
18	Antidepressant response and intolerance to SSRI is not influenced by G-protein β3 subunit gene C825T polymorphism in Japanese major depressive patients 2008 ·Progress in Neuro-Psychopharmacology and Biological Psychiatry ·Masaki Kato, Masataka Wakeno, Gaku Okugawa, Tsuyoshi Fukuda, Yoshiteru Takekita, (unknown), Junichi Azuma, Toshihiko Kinoshita, Alessandro Serretti	26
19	No Association of TPH1 218A/C Polymorphism with Treatment Response and Intolerance to SSRIs in Japanese Patients with Major Depression 2007 ·Neuropsychobiology ·Masaki Kato, Masataka Wakeno, Gaku Okugawa, Tsuyoshi Fukuda, Junichi Azuma, Toshihiko Kinoshita, Alessandro Serretti	29
20	Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism 2005 ·International Clinical Psychopharmacology ·Masaki Kato, Yuka Ikenaga, Masataka Wakeno, Gaku Okugawa, Kenji Nobuhara, Tsuyoshi Fukuda, Kazuhiro Fukuda, Junichi Azuma, Toshihiko Kinoshita	66

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact